Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial

BACKGROUND: Immunoglobulin E (IgE) and immunoglobulin G4 (IgG4) to peanut and its components may influence the clinical reactivity to peanut.

Allergen‐specific immunotherapy is known for modifying both IgE and IgG4.

Peanut oral immunotherapy may influence these serological parameters.

METHODS: Exploratory analyses of serological data from participants receiving peanut (Arachis hypogaea) allergen powder‐dnfp (PTAH) and placebo in the double‐blind, randomized, phase 3 PALISADE trial were conducted to evaluate potential relationships between peanut‐specific and peanut component–specific (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, and Ara h 9) IgE and IgG4 levels and clinical outcomes.

RESULTS: A total of 269 participants (PTAH, n = 202; placebo, n = 67) were analyzed.

No relationship was observed between specific IgE and IgG4 levels at screening and maximum tolerated peanut protein dose during screening or response status during exit double‐blind placebo‐controlled food challenge (DBPCFC).

In PTAH‐treated participants, no relationship was observed between IgE and IgG4 levels at screening and maximum symptom severity during exit DBPCFC.

Postscreening ratios (ie, postscreening/screening) in the PTAH group were significant at the end of updosing and exit visit for most components.

Postscreening changes in specific IgE levels were more pronounced with PTAH versus placebo for most components.

CONCLUSIONS: Specific IgE and IgG4 levels at screening are not correlated with screening or exit DBPCFC results, and are not predictive of clinical response to PTAH.

Peanut (Arachis hypogaea) allergen powder‐dnfp contains the relevant and immunodominant allergens, inducing immunological changes with the treatment.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02635776.